Related Experiment Videos
Multiple sclerosis: cell-mediated immunity to human brain gangliosides
E Beraud1, M M Golstein, F Viallet
1Laboratoire d'Immunopathologie, Faculté de Médecine, Marseille.
Autoimmunity
|January 1, 1990
Summary
Cell-mediated immunity (CMI) to gangliosides is heightened during Multiple Sclerosis (MS) attacks. Leukocyte Migration Inhibition (LMI) tests reveal increased hypersensitivity to these glycolipids in active MS patients.
Area of Science:
- Neuroimmunology
- Autoimmunity
Background:
- Cell-mediated immunity (CMI) to myelin components is implicated in Multiple Sclerosis (MS) pathogenesis.
- Gangliosides are a recently suggested target in MS, unlike Myelin Basic Protein with controversial findings.
Purpose of the Study:
- To investigate the involvement of gangliosides in MS pathogenesis.
- To assess cell-mediated immune response to human brain gangliosides in MS patients.
Main Methods:
- Leukocyte Migration Inhibition (LMI) tests were performed using human brain gangliosides.
- Participants included 39 MS patients (24 definite), 29 with Other Neurological Diseases (OND), 36 with Inflammatory Diseases (ID), and 40 healthy controls.
- MS patients were stratified by clinical stage (attack vs. no attack).
Main Results:
- The mean migration inhibition percentage in the MS-attack group was significantly higher (p < 0.01) compared to MS without attack, OND, ID, and healthy controls.
- Specifically, the MS-attack group showed 24.4 +/- 16.2% inhibition.
- LMI to gangliosides was significantly increased during the active MS attack stage.
Conclusions:
- These findings support the hypothesis of a Delayed Type Hypersensitivity (DTH) to gangliosides during active MS.
- CMI to gangliosides may play a role in the pathogenesis of Multiple Sclerosis during its active phase.